| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LYG1 |
| Uniprot No | Q8N1E2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-194aa |
| 氨基酸序列 | S NWGCYGNIQS LDTPGASCGI GRRHGLNYCG VRASERLAEI DMPYLLKYQP MMQTIGQKYC MDPAVIAGVL SRKSPGDKIL VNMGDRTSMV QDPGSQAPTS WISESQVSQT TEVLTTRIKE IQRRFPTWTP DQYLRGGLCA YSGGAGYVRS SQDLSCDFCN DVLARAKYLK RHGF |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LYG1重组蛋白的3篇参考文献示例(注：以下内容为模拟示例，实际文献需根据具体研究检索)：
1. **《重组LYG1蛋白的制备及其抗菌功能研究》**
作者：Zhang et al.
摘要：本研究通过大肠杆菌表达系统成功克隆并纯化了LYG1重组蛋白，体外实验表明其对金黄色葡萄球菌等革兰氏阳性菌具有显著抑菌活性，为LYG1的抗菌机制研究提供了基础。
2. **《LYG1在先天免疫中的调控作用：基于重组蛋白的功能分析》**
作者：Li et al.
摘要：通过构建LYG1重组蛋白，研究发现其能够激活巨噬细胞的NF-κB信号通路，增强炎症因子IL-6和TNF-α的分泌，提示LYG1在宿主免疫防御中的潜在作用。
3. **《昆虫细胞表达系统中LYG1重组蛋白的高效生产与结构鉴定》**
作者：Wang et al.
摘要：采用杆状病毒-昆虫细胞系统优化了LYG1重组蛋白的表达条件，并通过质谱和圆二色谱验证其正确折叠，为后续药物开发提供了高纯度蛋白来源。
**提示**：若实际检索结果有限，建议扩展检索关键词(如“LYG1 protein”“recombinant lysozyme-like protein”)，或查询专业数据库(PubMed、Web of Science)获取最新文献。
**Background of LYG1 Recombinant Protein**
LYG1 (Lysozyme G-like 1) is a member of the lysozyme superfamily, a group of enzymes traditionally recognized for their bacteriolytic activity through hydrolysis of bacterial cell wall peptidoglycans. While lysozymes are widely studied in innate immunity, LYG1 represents a less characterized but emerging protein of interest. It shares structural homology with canonical lysozymes, including conserved catalytic residues, yet exhibits distinct functional and regulatory features. Genomic studies suggest that *LYG1* is evolutionarily conserved across vertebrates, hinting at its biological significance.
The recombinant form of LYG1 is engineered using genetic cloning techniques, typically expressed in prokaryotic (e.g., *E. coli*) or eukaryotic systems (e.g., mammalian cells) to ensure proper folding and post-translational modifications. Recombinant LYG1 enables researchers to study its biochemical properties, substrate specificity, and interactions without relying on native sources. Recent studies propose roles beyond antimicrobial defense, including modulation of inflammatory responses, tissue repair, and potential involvement in cancer biology. For instance, altered LYG1 expression has been observed in certain tumors, suggesting a dual role in both host defense and disease progression.
Research on LYG1 also explores its therapeutic potential. Its enzymatic activity against pathogens positions it as a candidate for antimicrobial therapies, while its immunomodulatory effects may inform treatments for chronic inflammation or autoimmune disorders. However, mechanistic details remain unclear, necessitating further structural and functional studies.
In summary, LYG1 recombinant protein serves as a critical tool for unraveling the protein’s multifaceted roles in health and disease, bridging gaps between lysozyme biology and novel clinical applications.
×
